A molecule called Alda-1 can repair Aldehyde dehydrogenase 2 (ALDH2), an often defective alcohol metabolism enzyme that affects an estimated 1 billion people worldwide, according to research published Jan. 10 in the advance online edition of Nature Structural and Molecular Biology. The findings suggest the possibility of a treatment to reduce the health problems associated with the enzyme defect.
After alcohol is consumed, it is metabolized into acetaldehyde, a toxic chemical that causes DNA damage. Aldehyde dehydrogenase 2 (ALDH2) is the main enzyme responsible for breaking down acetaldehyde into acetate, a nontoxic metabolite in the body. It also removes other toxic aldehydes that can accumulate in the body.
About 40 percent of the East Asian population, and many people of East Asian descent throughout the world, carry a genetic mutation that produces an inactive form of ALDH2. When individuals with the ALDH2 mutation drink alcohol, acetaldehyde accumulates in the body, resulting in facial flushing, nausea, and rapid heartbeat. In addition to its link to increased cancer risk, the inactive form of ALDH2 also reduces the effectiveness of nitroglycerin. Nitroglycerin is a drug to treat angina, chest pain that occurs when the heart doesn't get enough oxygen-rich blood.
In a series of experiments that examined the interaction between Alda-1 and the defective ALDH2 enzyme, researchers found that Alda-1 restored the structure of the inactive enzyme. The normal, active form of ALDH2 creates a catalytic tunnel, a space within the enzyme in which acetaldehyde is metabolized, explained Dr. Hurley. In the defective enzyme, the tunnel does not function properly. Alda-1 binds to the defective enzyme in a way that effectively reopens the catalytic tunnel and thus allows the enzyme to metabolize acetaldehyde
"The manner in which Alda-1 binds to the structure of ALDH2 provides us with powerful insight into the relationships between activators and inhibitors of this crucial detoxifying enzyme," says Dr. Hurley. "This insight will lead to the modification of Alda-1 to improve its potency, and also opens up the possibility of designing new analogs that can selectively affect the metabolism of other molecules that are detoxified by aldehyde dehydrogenase."
"This intriguing finding could have broad public health implications," said NIAAA Acting Director Kenneth R. Warren, Ph.D. "We look forward to further research aimed at translating these laboratory discoveries into possible treatments for people."
Citation: Perez-Miller et al., 'Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant', Nature Structural and Molecular Biology Online, January 2010; doi:10.1038/nsmb.1737
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- What May Be Missing From Quantum Computing - A Quantum Middle Man
- Math, Time and Obesity
- Almost One In Three US Adults Owns A Gun But Murder Rates Have Plummeted
- Patients With Recurrent Depression Have Smaller Hippocampi
- Radiation Detectors Click By Design
- Obese Teens Are Less Likely To Use Contraception
- Phase IIb Pivotal Clinical Study Of P2B001 For The Treatment Of Early Stage Parkinson's Disease
- "Sorry Laaz, this comment is not directly related to the content in this blog and will be deleted..."
- "Nice catch, thank you...."
- "The chart (and the framing by the underlying statstics) is making more of an evangelical case than..."
- "For the data, see Richardson EG1, Hemenway D. 2011: Homicide, suicide, and unintentional firearm..."
- "Hello IR,if you apply to one of the positions we'll open next month (5 or 6 if I'm not mistaken)..."